We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

73 hedge funds and large institutions have $96.8M invested in Merrimack Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

888% more call options, than puts

Call options by funds: $553K | Put options by funds: $56K

23% more capital invested

Capital invested by funds: $78.7M → $96.8M (+$18.1M)

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

39% less funds holding

Funds holding: 119 → 73 (-46)

80% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 55

Holders
73
Holders Change
-46
Holders Change %
-38.66%
% of All Funds
1.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
28
Reduced
25
Closed
55
Calls
$553K
Puts
$56K
Net Calls
+$497K
Net Calls Change
+$728K

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$5.21M
2
RCMNY
Rubric Capital Management (New York)
New York
+$4.51M
3
WIM
Wittenberg Investment Management
Massachusetts
+$869K
4
QIM
Quantitative Investment Management
Virginia
+$573K
5
CS
Credit Suisse
Switzerland
+$435K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.91M
2
Norges Bank
Norges Bank
Norway
-$1.65M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$930K
4
CS
Candriam SCA
Luxembourg
-$708K
5
Morgan Stanley
Morgan Stanley
New York
-$455K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
101
BlueCrest Capital Management
Jersey
– -$32K -3,305 Closed
PPSG
102
Princeton Portfolio Strategies Group
New Jersey
– -$32K -3,297 Closed
LPL Financial
103
LPL Financial
California
– -$32K -3,283 Closed
WP
104
WMS Partners
Maryland
– -$32K -3,254 Closed
HK
105
Horizon Kinetics
New York
– -$31K -3,178 Closed
QC
106
QCM Cayman
Texas
– -$30K -3,048 Closed
WS
107
Wedbush Securities
California
– -$28K -2,860 Closed
DTL
108
Dynamic Technology Lab
Singapore
– -$27K -2,706 Closed
Principal Financial Group
109
Principal Financial Group
Iowa
– -$25K -2,613 Closed
AMG
110
Asset Management Group
Connecticut
– -$24K -2,472 Closed
D.E. Shaw & Co
111
D.E. Shaw & Co
New York
– -$23K -2,398 Closed
AA
112
Alesco Advisors
New York
– -$22K -2,228 Closed
AB
113
Amalgamated Bank
New York
– -$20K -2,091 Closed
Two Sigma Advisers
114
Two Sigma Advisers
New York
– -$18K -1,881 Closed
NA
115
NewEdge Advisors
Louisiana
– -$20.1K -1,787 Closed
BFM
116
Boothbay Fund Management
New York
– -$17K -1,766 Closed
Balyasny Asset Management
117
Balyasny Asset Management
Illinois
– -$16K -1,627 Closed
QI
118
QS Investors
New York
– -$15K -1,563 Closed
Teacher Retirement System of Texas
119
Teacher Retirement System of Texas
Texas
– -$14K -1,390 Closed
CB
120
Chemical Bank
Michigan
– -$12K -1,271 Closed
AIM
121
Acrospire Investment Management
Illinois
– -$5K -474 Closed
DADC
122
D.A. Davidson & Co
Montana
– -$1K -203 Closed
AG
123
Advisor Group
Arizona
– -$1K -127 Closed
MWM
124
Mascoma Wealth Management
New Hampshire
– -$1K -127 Closed
HIIFS
125
Harel Insurance Investments & Financial Services
Israel
– -$3K -8 Closed
1 2 3 4
5

MACK Hedge Fund Activity: Q3 2017 in Review

73 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2017, worth a combined $96.8M — up 23% from $78.7M a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of MACK and 11 opened new positions — a net loss of 44 holders — while 25 trimmed existing stakes and 28 added.

The largest buyer was Newtyn Management, opening a new position worth an estimated $5.21M. The largest seller was Fidelity Investments, cutting an estimated $1.91M.

  • 73 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2017, down from 119 in Q2 2017.
  • Funds reported $96.8M of Merrimack Pharmaceuticals, Inc. stock for Q3 2017, up 23% quarter-over-quarter.
  • 11 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2017 and 55 closed out, a net change of -44 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2017 was Newtyn Management, an estimated $5.21M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $1.91M sold.

Based on aggregated 13F filings for Q3 2017.